Pre-Shave Gel and Brush in Pseudofolliculitis Barbae

Pseudofolliculitis Barbae Clinical Trial

Official title:

The Impact of a Pre-Shave Gel and Brush in Males With Pseudofolliculitis Barbae

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03043534
• Other study ID #: IRB00034479
• Status: Completed
• Phase: N/A
• Start date: November 12, 2015
• Est. completion date: October 12, 2016

Study information

• Verified date: November 2018
• Source: Wake Forest University Health Sciences
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This will be a randomized investigator blinded study of 40 men age 20-60 (inclusive) with symptoms of mild-moderate PFB based on Investigator Global Assessment (IGA). Subjects will be divided into two groups: the Control group of 20 subjects and the Experimental group of 20 Subjects. Subjects will be seen at Screening/Baseline, and 6 weeks.

All subjects will use their normal razors and shave products during the six week study. The Experimental group of subjects will also be given the study product Pre-Shave Gel and Cleansing Brush.

Description:

This will be a randomized investigator blinded study of up to 40 men age 20-60 (inclusive) with symptoms of mild-moderate PFB based on Investigator Global Assessment (IGA). Subjects will be divided into two groups: the Control group of 20 subjects and the Experimental group of 20 Subjects. Subjects will be seen at Screening/Baseline, and 6 weeks.

All subjects will use their normal razors and shave products during the six week study. The Experimental group of subjects will also be given the study product Pre-Shave Gel and Cleansing Brush. The study gel and brush will be used prior to their normal shave routine.Quantitative lesion counts will be done by trained clinicians at each visit. Efficacy assessments include Investigator Global Assessment (IGA) scoring

Recruitment information / eligibility

• Status: Completed
• Enrollment: 29
• Est. completion date: October 12, 2016
• Est. primary completion date: October 12, 2016
• Accepts healthy volunteers: No
• Gender: Male
• Age group: 20 Years to 60 Years

Eligibility

Inclusion Criteria:

1. Males with at least a two year history of the symptoms of PFB.

2. Must be age 20-60 years of age (inclusive).

3. Must wet shave using just a prep and blade razor at least 3 or more times per week, and be willing to continue that regimen during the study.

4. Must have Mild -to moderate PFB based on IGA rating scales. There are no lesion count inclusion requirements.

Exclusion Criteria:

1. Use of systemic (oral antibiotics) within the last 4 weeks.

2. Use of topical prescriptions (topical clindamycin, topical retinoids, topical metronidazole, topical sulfacetamide/sulfur, topical adapalene, benzoyl peroxide, salicylic acid, glycolic acid, retinol,chemical peels) or over-the-counter products the subject has used for PFB or Hair Growth within the last 2 weeks. Use of oral retinoids, laser therapy or electrolysis treatments or waxing in beard area in last 12 months.

3. Individuals who do not wet shave with a bladed razor, or who use electric shavers.

4. Subjects must not have used any type of cleansing or shave brush to the face for six weeks prior to Baseline.

5. Individuals who have removed a beard within last two months.

6. Individuals who have a history of alopecia areata of the face.

7. Confounding dermatological conditions that would, in the opinion of the principal investigator, preclude participation in this study such as:

• Immune deficiency disease (HIV positive, AIDS, sarcoidosis)

• On immunosuppressive drugs (e.g. oral corticosteroids)

• Autoimmune disease (lupus, scleroderma, diabetes mellitus, vitiligo)

• Koebnerizing diseases (e.g. psoriasis, lichens planus, (HPV) human papilloma virus, facial verruca, molluscum contagiosum)

• Tuberculosis, Hepatitis B

• History of Keloids

• History of Herpes simplex in treated area

• Bacterial infection of face including abscesses and draining sinuses of facial area

• Cystic Acne, other acne in bearded area which interferes with shaving as well as the ability to distinguish PFB lesions from acne

Related Conditions & MeSH terms

• Pseudofolliculitis Barbae

Intervention

Other:
• shave gel
Non marketed pre-shave gel with the following INCI list of ingredients: WATER, GLYCERIN, DIMETHICONE, LAURETH-23, PETROLATUM, ACRYLAMIDE/SODIUM ACRYLOYLDIMETHYLTAURATE COPOLYMER, ISOPROPYL PALMITATE, HYDROXYETHYLCELLULOSE, FRAGRANCE, PEG-23M, C13-14 ISOPARAFFIN, DMDM HYDANTOIN, DISODIUM EDTA, LAURETH-7, IODOPROPYNYL BUTYLCARBAMATE
• Brush
All subjects randomized to brush will use the brush with each shave

Locations

Country	Name	City	State
United States	Wake Forest University Health Sciences Dept of Dermatology	Winston-Salem	North Carolina

Sponsors (1)

Lead Sponsor	Collaborator
Wake Forest University Health Sciences

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Patient Global Severity Assessment- Mechanics of Shaving	A total of the Patient's Global Assessment of mechanics of shaving based on following scale: How easy is it to… (please rank each phrase from 1 to 4; 1 = very easy, 2 = easy, 3 = difficult, 4 = very difficult); A) get a smooth shave after shaving? __________; B) shave stubborn hairs? __________; C) shave against the grain with little irritation? __________; D) shave with the grain with little irritation? __________; E) glide comfortably over your skin with the razor blade?; For each subject, the total score could range from 5 -20, with lower numbers indicating better shave mechanics	Baseline, 6 weeks
Secondary	Patient Global Severity Assessment (Degree of Itching, Burning and Stinging)	Patient Global Severity Assessment measures itching/burning/stinging on the following scales:1 (no itching/no burning/no stinging at all) to 5 (very severe) the total score could range from 1-5 with the lower scores promoting a better outcome.	Baseline, 6 weeks
Secondary	Quality of Life Survey	Quality of Life Survey will measure subjects' overall perception. For Shaving Experience, the total score could range from 6-42 with lower scores denoting better outcome measures.; For Shaving Frustration, the total score could range from 3-21 with higher scores denoting better outcome measures.; For Achieving Results, the total score could range from 3-21 with lower scores denoting better outcome measures.; For Skin Feel, the total score could range from 3-21 with lower scores denoting better outcome measures.; For Skin-Confidence, the total score could range from 4-28 with lower scores denoting better outcome measures.; For Social Interactions, the total score could range from 6-42 with lower scores denoting better outcome measures.	Baseline, 6 weeks
Secondary	Lesions	Lesions will be measured by counting papules, pustules, ingrown hairs, and Hyerpigmentation.	Baseline, 6 weeks
Secondary	Investigator Global Assessment (IGA)	Investigator Global Assessment (IGA) will measure disease severity using a scale 0 (Clear) - 5 (Very Severe) with the lower score grade denoting better outcome measures.	Baseline, 6 weeks